
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health is experiencing a period of slower revenue growth, attributed to a slight decline in chronic therapies revenue and challenges related to patient census declines. Despite this, the company has potential growth levers identified for the second half of the year and expects a ramp in adjusted EBITDA to 55-57%. Additionally, the company has a comprehensive approach to data collection and analysis from over 200,000 sources in 38 languages, which could provide valuable insights and opportunities for growth.
Bears say
Option Care Health is facing headwinds in revenue and profit due to unexpected Stelara-related challenges and slower-than-expected growth in certain specialty therapies. The company's revised financial guidance for 2026 includes a reduced revenue forecast and lower-than-expected cash flow from operations, leading investors to doubt the achievability of the company's targets. Additionally, Option Care's exposure to Stelara is expected to significantly decrease after 2026, but the company is facing launch delays and slower-than-anticipated growth in certain therapies. These challenges could hinder the company's ability to meet its revenue and profit targets and may lead to downside risks for investors.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares